Awesome Variances “First break all the rules” Carolyn Te Young & Jed Gorlin ABC 7/04.

Slides:



Advertisements
Similar presentations
High Throughput Donor Plasma NAT Screening Assay Applied to Acute HIV Detection in a Public Health Setting December 5, 2007 Josh Goldsmith, Ph.D. National.
Advertisements

CBER Whole Blood and Blood Components Diane K. Hall Consumer Safety Officer CBER, OBRR, DBA September 16, 2009.
License Supplements under 21 CFR
Maintaining a Safe and Adequate Supply of Donated Blood During a Severe Emergency Alan E. Williams, Ph.D. Associate Director for Regulatory Affairs, OBRR,
FABB HOT TOPICS Current Issues in Blood Banking Ron Jackson Director, Compliance Branch FDA FLORIDA DISTRICT June 7, 2013.
Supplemental Testing of Donors for HIV and HCV September 18, 2003 BPAC Meeting Robin Biswas, M.D. Indira Hewlett, Ph.D. FDA/CBER/OBRR/DETTD.
Blood Donor Written Statement of Understanding
Comparing the New EIAs with Old Standbys: Florida Bureau of Laboratories Verification Data HIV Diagnostics: New Developments and Challenges Feb. 28, 2005.
Draft Guidance for Industry: Preventive Measures to Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease (CJD) and Variant Creutzfeldt-Jakob.
Development of Guidance Documents Jennifer Scharpf, M. P. H
CBER 510(k) Challenges and Strategies Susan Finneran Director of Clinical and Regulatory Affairs.
Hello. Blood Transfusion What is a Blood Transfusion? Blood transfusion is a medical procedure that needs to be ordered by a physician. It is the introduction.
Public Workshop: Quarantine Release Errors in Blood Establishments September 13, 2011 QREs Past, Present and Future Sheryl A. Kochman Deputy Director Division.
CBER Whole Blood and Blood Component Labeling Jennifer Jones Consumer Safety Officer CBER, OBRR, DBA September 16, 2009.
The Safety of the Blood Supply
Americas Technical Advisory Group ICCBBA ISBT 128 Blood Product Labeling – A Hospital Perspective Americas Technical Advisory Group ICCBBA.
Current standards, donor safety, and blood supply
CBER Cooperative Manufacturing Arrangements (Contractors) Jennifer Jones Consumer Safety Officer CBER, OBRR, DBA September 15, 2009.
Guidelines for Laboratory Testing and Result Reporting for Antibody to Hepatitis C Virus Miriam J. Alter, Ph.D. Division of Viral Hepatitis Centers for.
Parvovirus B19 NAT for Whole Blood and Source Plasma Introduction and Background Mei-ying W Yu, PhD DH/OBRR/CBER/FDA 75 th Blood Products Advisory Committee.
CBER Blood Establishment Registration and Product Listing Jan O’Brien Blood Registration Coordinator DBA, OBRR, CBER September 15, 2009.
Draft Guidance: Collection of Platelets by Automated Methods Comments to the Docket and Questions for the Committee Alan E. Williams, Ph.D. Director,
1 Quality Control Procedures During Autotransfusion AmSECT New Advances in Blood Management Meeting Seattle, Washington September 8, 2011John Rivera.
1 Hot Topics New Blood and Plasma Issues Barbara Carmichael Investigator, U.S. Food & Drug Administration Florida District - Jacksonville, FL Resident.
Pooled Source Plasma NAT for HIV-1 An Update from the Bayer HIV-1 IND Study Barbara Masecar Bayer Corporation Raleigh, NC Blood Products Advisory Committee.
FDA Guidance for Industry: Use of Serological Tests to Reduce the Risk of Transmission of Trypanosoma cruzi Infection in Whole Blood and Blood Components.
BioLife Plasma Services Experience with HBV NAT Testing
And the order changeth …. Evolving protocols for TTI testing
Reentry for Donors Deferred Based on Anti-HBc Test Results November 3, 2005 BPAC Meeting FDA/CBER/OBRR/DETTD.
FDA’s Current Considerations of Parvovirus B19 Nucleic Acid Testing (NAT) Mei-ying W. Yu, PhD Division of Hematology CBER/FDA Extraordinary SoGAT Meeting.
CBER Review Considerations on Source Plasma Vaccination Programs Judy Ellen Ciaraldi BS, MT(ASCP)SBB, CQA(ASQ) CBER, OBRR, DBA September 16, 2009.
IN THE NAME OF GOD Blood Safety S. AMINI KAFI ABAD CLINICAL AND ANATOMICAL PATHOLOGIST IRANIAN BLOOD TRANSFUSION ORGANIZATION(IBTO) RESEARCH CENTER June.
1 OraQuick ® ADVANCE ™ HIV 1/2 Antibody Test (Oral Fluid Specimen Type) Blood Products Advisory Committee Meeting March 10, 2006.
CBER 1 Establishment Submissions Rosia E. Nesbitt, BS, SBB(ASCP), CQA(ASQ) Consumer Safety Officer CBER, OBRR, DBA September 15, 2009.
CBER Red Blood Cell Immunization Programs Judy Ellen Ciaraldi BS, MT(ASCP)SBB, CQA(ASQ) CBER, OBRR, DBA September 16, 2009.
Maria Rios, Ph.D. CBER/FDA Blood Products Advisory Committee May 1st, WNV Epidemiology & FDA’s Recommendations on the Use of NAT to Reduce the.
Current Considerations on Plasma for Further Manufacturing Obtained from Whole Blood Donors Alan E. Williams, Ph.D. Associate Director for Regulatory Affairs,
Approval Criteria for Assays for Testing Blood Donors for West Nile Virus Robin Biswas, M.D. CBER, FDA Blood Products Advisory Committee Meeting March.
Apheresis Blood Components
FDA Recommendations: Sampling Plans for Blood Establishments Lore Fields MT(ASCP)SBB Consumer Safety Officer OBRR/CBER/FDA October 19, 2012.
REGULATIONS FOR BLOOD and BLOOD PRODUCTS JILL HOAG BS, SBB(ASCP) CQA(ASQ) AABB STAFF LEAD ASSESSOR 1.
Leukocyte-Reduced Blood Components Lore Fields MT(ASCP)SBB Consumer Safety Officer, DBA, OBRR, CBER September 16, 2009.
CBER’s Blood Safety Team Blood Products Advisory Committee 01 May 2008 Jonathan C. Goldsmith, MD Office of Blood Research and Review.
E001372A 1 ARC Experience with Indeterminate Blood Donors Susan L. Stramer, Ph.D. National Confirmatory Testing Laboratory American Red Cross.
CBER Alternative Procedures “Variances” Judy Ellen Ciaraldi BS, MT(ASCP)SBB, CQA(ASQ) CBER, OBRR, DBA September 15, 2009.
1 B19 Testing of Plasma for Fractionation: Current Thinking Mei-ying W Yu, PhD Division of Hematology CBER/FDA SoGAT XVII May 26-27, 2004.
E A 1 Supplemental Testing for HIV-1 and HCV Blood Products Advisory Committee Meeting September 18, 2003 Susan L. Stramer, Ph.D. National Testing.
12 th Annual FDA & the Changing Paradigm for Blood Regulation – 01/16/2009 – Las Vegas, NV – Gilliam B. Conley 1 FDA perspective on “Where are we? Where.
Blood Center Experience with Double Red Cell Collections by Apheresis: Adverse Events and Impact on Capacity Brian Custer, Hany Kamel, Marj Bravo Peter.
FDA Update: Particulate Matter Task Force Sharyn Orton, Ph.D. OBRR/CBER/FDA Blood Products Advisory Committee Meeting June 19, 2003.
Revised Recommendations for the Assessment of Donor Suitability: West Nile Virus Sharyn Orton, Ph.D. OBRR/CBER/FDA Blood Products Advisory Committee Meeting.
Concurrent and Component Plasma: CBER Considerations on Standards and Labeling BPAC April 28, 2011 Mark Weinstein, Ph.D. Office of Blood Research and Review.
Issues Related to Implementation of Blood Donor Screening for Infection with Trypanosoma cruzi Presentation to BPAC April 26, 2007 Robert Duncan, PhD.
Management of Donors and Units that Test HBV NAT Positive: Current Considerations July 21, 2005 BPAC Meeting Robin Biswas, M.D. FDA/CBER/OBRR/DETTD.
Comparability Protocols Lore Fields MT(ASCP)SBB Consumer Safety Officer DBA/OBRR/CBER September 16, 2009.
CBER Source Plasma Labeling Judy Ellen Ciaraldi BS, MT(ASCP)SBB, CQA(ASQ) CBER, OBRR, DBA September 16, 2009.
Minimizing the Risks of TSE Agents in Human Tissues Melissa A. Greenwald, M.D. Division of Human Tissues Office of Cellular, Tissue and Gene Therapies;
Jaro Vostal, MD, PhD Division of Hematology, OBRR, CBER, FDA
CLIA Waiver for the OraQuick ® Rapid HIV-1 Antibody Test Elliot P. Cowan, Ph.D. Senior Regulatory Scientist Office of Blood Research and Review Center.
E B—Anti-HBc Chart 1 10/2004 Anti-HBc Testing and Donor Reentry Results of a Pilot Study Susan L. Stramer, Ph.D. American Red Cross Blood Products.
Donor Suitability and Blood and Blood Product Safety in Cases of Known or Suspected West Nile Virus Infection - Update - Alan E. Williams, Ph.D. Director,
Human Specimen Repositories Requirements of 21 CFR Parts 50 & 56 PRIM & R May 5, 2004 Sally A. Hojvat, Ph.D. Director of Microbiology Devices Office of.
CBER Update on status of West Nile virus test, lot release and validation panel development Indira Hewlett, Ph.D CBER/FDA Blood Products Advisory Committee.
BioPlex 2200 HIV Ag-Ab Assay
CBER Current Considerations for Blood Donor Screening for West Nile Virus Pradip N. Akolkar, Ph.D. Maria Rios, Ph.D. DETTD, OBRR Blood Products Advisory.
Incorporation of NAT into supplemental testing of HCV and HIV seroreactive donors Michael P. Busch representing Blood Systems Research Institute Blood.
Results Methods A Five-Year Snapshot of Our Hereditary Hemochromatosis Program: A Work in Progress P Davenport 1, D Echols 1, J Giacoletti 1, L Sutor 1,2,
Donations After Reentry
Presented by Karen Dosanjh Quality Director Blood Systems
Challenges for Blood Donor Confirmatory Testing Algorithms
Presentation transcript:

Awesome Variances “First break all the rules” Carolyn Te Young & Jed Gorlin ABC 7/04

Variances: An underused tool RIBC has been granted variances for: Tattoos: applied in licensed parlors Hemochromatosis: hct down to 34% ml using 500 ml bag- may use HIV WB indeterminate- case by case reinstatements following adverse lots HCV RIBA indeterminate-case by case

Exceptions and Alternatives approved under 21 CFR “The director for CBER may approve an exception or alternative procedure to any requirement in subchapter F (biologics) of Chapter 1(Parts ) of title 21 CFR. Both licensed and unlicensed establishments must submit requests: Guidance for Industry: Changes to an approved Application: July 2001)

Tattoos First applied to AABB for variance: Deferred by AABB Standards and TTD committee pending review by FDA. Granted by FDA for licensed parlors- limited to tattoos only, not other piercing Granted by AABB Standards July 2002 Single use needles AND pigments only

Hemochromatosis RIBC has standard variance allowing more frequent donations and not requiring labeling. BUT, they also were granted the ability to draw donors down to a hct of 34% provided the donation volume is between ml using the 500ml bag. Logic: RBC mass > than 405 ml from donor with 38% hct

ml: Short units In the event that less than 449 mls obtained from a donor with hct > 38%, but > 405 ml, then RIBC uses the unit as a regular unit, since the RBC mass exceeds that obtained from a standard draw using a 450 ml bag.

HIV-Western blot indeterminate MBC acts as confirmatory testing center for RIBC. MBC was using Calypte for HIV WB. Quality of HIV WB deteriorated significantly in , resulting in very high rate of unreadable or indeterminate WB. One time approval for re-entry of selected donors affected by these tests allowed.

Other one time donor variances For a few individuals with HCV reactive ab, indeterminate RIBA and negative singlet NAT testing, approval for re-entry of donor has been allowed.

Other approved variances 21 CFR (e) Use of NAT testing for other types of donors? Use of EIA testing for specimens with high fat 21 CFR Ship autologous blood untested (test subsequent unit) 21 CFR 640.4, : Allow use of components exposed to temperatures up to 17C up to 2 hours and 15 minutes.

Other approved variances (cont.) 21 CFR Allow syphilis testing on substitute sample drawn 1 day later 21 CFR a Allow use of 325 RBC exposed to 1 to –3oC for up to 4 hours provided each unit examined for hemolysis! 21CFR Allow use of A and AB FFP warmed to –4C over an 18 hour period with consignee notification. Also allow FFP manufacture when frozen within 24 hours after collection.

Ortho Hepatitis B sAg system 3 This “new improved, more sensitive test” also had up to 10 fold more false positives! Pending switch to alternative test, blood centers may apply for a one time variance to have falsely deferred donors reinstated after negative BioRad test. (UBS (+ others?) currently offering this reinstatement pathway testing)

HCT variance for plateletpheresis MBC will apply for variance to allow platelet collections from donors with 36% hct. Current machines lose few RBC if procedure halted. European rules allow platelet donations at a lower hct. Machines validated for use with lower hcts. Beth Israel in Boston (Transfusion report?) previously published efficacy of this variance.